CareDx: Wells Fargo downgrades to Equal-Weight, PT to $14 from $19.
ByAinvest
Friday, Aug 8, 2025 11:40 am ET1min read
CDNA--
CareDx reported earnings of $0.1 per share, missing the Zacks Consensus Estimate of $0.12 per share. This compares to earnings of $0.25 per share a year ago. The quarterly report represents an earnings surprise of -16.67%, indicating a significant drop from the previous year. However, it is important to note that this quarterly report includes non-recurring items.
Revenue for the quarter ended June 2025 was $86.68 million, which missed the Zacks Consensus Estimate by 4.45%. This compares to year-ago revenues of $92.27 million. Despite the revenue miss, the company has topped consensus revenue estimates two times over the last four quarters.
Wells Fargo cited several factors in its decision to downgrade the stock and reduce the price target. The investment bank noted that CareDx's earnings per share (EPS) missed expectations and that the company's revenue growth has slowed. Additionally, the firm cited concerns about the company's ability to maintain its growth trajectory in the face of increasing competition in the molecular diagnostics market.
Despite the downgrade, analysts remain optimistic about CareDx's long-term prospects. The company has shown a history of exceeding earnings expectations and has a strong pipeline of new products. Additionally, the company's recent acquisition of Cepheid has positioned it to expand its market share in the molecular diagnostics market.
Investors should closely monitor CareDx's earnings calls and future earnings expectations to gauge the company's performance and potential recovery. The sustainability of the stock's immediate price movement will largely depend on management's commentary on the earnings call.
References:
[1] https://www.nasdaq.com/articles/caredx-cdna-lags-q2-earnings-and-revenue-estimates
[2] https://www.investing.com/news/analyst-ratings/caredx-cdna-lags-q2-earnings-and-revenue-estimates
WFC--
CareDx: Wells Fargo downgrades to Equal-Weight, PT to $14 from $19.
Wells Fargo has downgraded its rating for CareDx (CDNA) to Equal-Weight and reduced its price target from $19.00 to $14.00. The investment bank's latest assessment comes after CareDx reported mixed earnings results for the second quarter of 2025. Despite the downgrade, the stock has shown resilience, with analysts noting the company's recent financial performance.CareDx reported earnings of $0.1 per share, missing the Zacks Consensus Estimate of $0.12 per share. This compares to earnings of $0.25 per share a year ago. The quarterly report represents an earnings surprise of -16.67%, indicating a significant drop from the previous year. However, it is important to note that this quarterly report includes non-recurring items.
Revenue for the quarter ended June 2025 was $86.68 million, which missed the Zacks Consensus Estimate by 4.45%. This compares to year-ago revenues of $92.27 million. Despite the revenue miss, the company has topped consensus revenue estimates two times over the last four quarters.
Wells Fargo cited several factors in its decision to downgrade the stock and reduce the price target. The investment bank noted that CareDx's earnings per share (EPS) missed expectations and that the company's revenue growth has slowed. Additionally, the firm cited concerns about the company's ability to maintain its growth trajectory in the face of increasing competition in the molecular diagnostics market.
Despite the downgrade, analysts remain optimistic about CareDx's long-term prospects. The company has shown a history of exceeding earnings expectations and has a strong pipeline of new products. Additionally, the company's recent acquisition of Cepheid has positioned it to expand its market share in the molecular diagnostics market.
Investors should closely monitor CareDx's earnings calls and future earnings expectations to gauge the company's performance and potential recovery. The sustainability of the stock's immediate price movement will largely depend on management's commentary on the earnings call.
References:
[1] https://www.nasdaq.com/articles/caredx-cdna-lags-q2-earnings-and-revenue-estimates
[2] https://www.investing.com/news/analyst-ratings/caredx-cdna-lags-q2-earnings-and-revenue-estimates
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet